Boston Scientific Secures $11 Billion in New Credit Facilities to Fund Penumbra Acquisition and General Operations

summarizeSummary

Boston Scientific secured $11 billion in new credit facilities, including a $6 billion term loan for the Penumbra acquisition and $5 billion in revolving credit, enhancing liquidity and supporting strategic growth.

check_boxKey Events

• New $3 Billion Revolving Credit Facility

  The company entered into a new $3.000 billion revolving credit agreement with a five-year maturity (February 26, 2031), replacing an existing facility. This facility includes a $500 million L/C Commitment and an $800 million Multicurrency Sublimit.

• New $2 Billion Short-Term Revolving Credit Facility

  A $2.000 billion 364-day revolving credit agreement was established, maturing 364 days from the earlier of the closing date or the consummation of the Penumbra acquisition. This facility has a $600 million Multicurrency Sublimit and is for general corporate purposes and acquisitions.

• New $6 Billion Delayed Draw Term Loan

  Boston Scientific secured a $6.000 billion 364-day delayed draw term loan agreement, specifically structured to fund the Penumbra acquisition. This includes a $1 billion Tranche A and a $5 billion Tranche B, with Tranche B requiring mandatory prepayment from future equity or debt issuances.

• Financing for Penumbra Acquisition

  These new credit facilities are primarily intended to finance the previously announced $14.5 billion acquisition of Penumbra, Inc., providing critical funding for this strategic transaction.

auto_awesomeAnalysis

Boston Scientific has significantly bolstered its financial flexibility by securing $11 billion in new credit facilities. This substantial financing package is crucial for funding the previously announced $14.5 billion acquisition of Penumbra, Inc., and for general corporate purposes. The inclusion of a $5 billion delayed draw term loan (Tranche B) with mandatory prepayment from future equity or debt issuances signals the company's intent to refinance this bridge financing, which could lead to further capital market activity. This move ensures liquidity and supports the company's strategic growth initiatives, especially important as the stock trades near its 52-week low.